An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Cenegermin (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dompe Spa
- 27 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2014 New source identified and integrated (European Clinical Trials Database; EudraCT2013-004271-12).
- 08 Apr 2014 New trial record